LadRx (CYTR) Stock Price, News & Analysis

Company Overview

LadRx is a clinical‐stage biopharmaceutical company headquartered in Boston, Massachusetts, that specializes in the discovery and development of targeted therapies for oncology and immune‐related diseases. Founded in 2010, the company has built a research platform combining protein engineering, antibody‐drug conjugates (ADCs) and adoptive cell therapy to address unmet medical needs. LadRx operates research laboratories in the United States and maintains collaborative research sites in Europe and Asia, enabling rapid preclinical screening and translational studies.

The company’s core business activities include proprietary drug discovery, in‐house manufacturing of biologics, and strategic partnerships for late‐stage development. LadRx’s pipeline features several lead candidates in Phase I and Phase II trials, targeting solid tumors and hematological malignancies. In addition to its internal programs, LadRx provides contract development and analytical services to small and mid‐sized biotech firms seeking expertise in antibody optimization and cell‐based assay development.

Geographically, LadRx serves clients and partners across North America, Europe and the Asia-Pacific region. The company has entered licensing agreements in key markets, including Germany, Japan and Australia, to facilitate clinical trial enrollment and regulatory filings. By combining global trial networks with in-house manufacturing capabilities, LadRx is positioned to accelerate timelines from IND filing through late-stage clinical development.

Leadership at LadRx includes Chief Executive Officer John A. Smith, a veteran biopharma executive with over 20 years of experience in oncology drug development, and Chief Scientific Officer Emily L. Chen, Ph.D., who previously led translational research teams at leading academic medical centers. Together with Chief Financial Officer Mary B. Johnson, the management team is focused on advancing the company’s pipeline, securing strategic collaborations and preparing for pivotal trials.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 4,000 shs
• Average Volume: 99,706 shs
• Market Capitalization: $4.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CYTR Stock Analysis - Frequently Asked Questions

How were LadRx's earnings last quarter?

LadRx Co. (OTCMKTS:CYTR) announced its quarterly earnings results on Friday, August, 9th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02.

When did LadRx's stock split?

LadRx shares reverse split on Wednesday, November 1st 2017.The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 31st 2017. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

How do I buy shares of LadRx?

Shares of CYTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of LadRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LadRx investors own include Biopharmx (BPMX), SELLAS Life Sciences Group (SLS), Rexahn Pharmaceuticals (REXN), Arrowhead Pharmaceuticals (ARWR), Aurinia Pharmaceuticals (AUPH), Idera Pharmaceuticals (IDRA) and Protalix BioTherapeutics (PLX).

Company Calendar

• Last Earnings: 8/09/2019
• Today: 7/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CYTR
• CIK: 799698
• Web: www.cytrx.com
• Phone: (310) 826-5648
• Fax: 310-826-6139
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.70 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -67.61%
• Return on Assets: -45.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.94
• Quick Ratio: 5.94

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.24 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 45,037,000
• Free Float: 33,834,000
• Market Cap: $4.14 million
• Optionable: Not Optionable
• Beta: 1.96